Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02324543 | Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT00965718 | Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer | completed | Phase 2 | 20 | GC Cell CorporationINDUSTRY | 1 | Jul 19, 2023 |
| clinicaltrials |
| NCT00042939 | Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 94 | Eastern Cooperative Oncology GroupNETWORK | 0 | Jul 6, 2023 | clinicaltrials |
| NCT02775695 | Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer | completed | Phase 2 | 12 | Medical College of WisconsinOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01684098 | Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor | completed | Phase 2 | 40 | EndocyteINDUSTRY | 0 | Jun 22, 2023 | clinicaltrials |
| NCT00003810 | Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT00049348 | Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02047513 | Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer(NEONAX) | completed | Phase 2 | 127 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02042378 | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | completed | Phase 2 | 19 | pharmaand GmbHINDUSTRY | 2 | Jun 13, 2023 | clinicaltrials |
| NCT00202800 | Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 40 | Corewell Health WestOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT02620865 | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT01845337 | Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine(TOFFEE) | completed | Phase 2 | 59 | University of EdinburghOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT02578732 | FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial | completed | Phase 2 | 28 | Brown UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT02194829 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02511223 | Efficacy and Safety of PARPi to Treat Pancreatic Cancer(10) | completed | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 19, 2023 | clinicaltrials |
| NCT02806687 | Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer(THERGAP-02) | completed | Phase 2 | 68 | University Hospital, ToulouseOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03717298 | Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 30 | Catalysis SLINDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03801915 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2023 | clinicaltrials |
| NCT02707159 | Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients(PACT-ACT-v6) | completed | Phase 2 | 70 | Helse Stavanger HFOTHER_GOV | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02210559 | A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 37 | Kyntra BioINDUSTRY | 1 | Mar 2, 2023 | clinicaltrials |
| NCT02028806 | mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 40 | Yuhong LiOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT01647828 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer(ALPINE) | completed | Phase 1 / Phase 2 | 217 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03977272 | Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer | completed | Phase 2 | 110 | Zhejiang UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02713529 | Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | completed | Phase 1 / Phase 2 | 117 | AmMax Bio, Inc.INDUSTRY | 6 | Jan 20, 2023 | clinicaltrials |
| NCT03331562 | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | completed | Phase 2 | 24 | Translational Genomics Research InstituteOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT01939665 | PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma(PANFIRE) | completed | Phase 1 / Phase 2 | 50 | Amsterdam UMC, location VUmcOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT02564146 | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine(ALPACA) | completed | Phase 2 | 325 | AIO-Studien-gGmbHOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT02428270 | A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02562716 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 19, 2022 | clinicaltrials |
| NCT01845805 | Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine) | completed | Phase 2 | 49 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT03158779 | Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 2 | 45 | Istituto Clinico HumanitasOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT01547260 | Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer(LENAGEM) | completed | Phase 1 / Phase 2 | 34 | Maria LiljeforsOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT04769414 | Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN) | completed | Phase 2 | 48 | Menoufia UniversityOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT02080221 | BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial | completed | Phase 2 | 50 | Brown UniversityOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT03086369 | A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 184 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 28, 2022 | clinicaltrials |
| NCT02022033 | BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial | completed | Phase 2 | 25 | Brown UniversityOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT02704156 | SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer | completed | Phase 2 | 170 | Changhai HospitalOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT02080260 | A Study of Regorafenib in Advanced Pancreatic Cancer Patients | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT02178709 | A Phase II Study of Neoadjuvant FOLFIRINOX | completed | Phase 2 | 48 | Indiana UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT01360593 | Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma | completed | Phase 2 | 35 | David A. Clump, MD, PhDOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT02131493 | S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer | completed | Phase 2 | 80 | Zhejiang UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT00617708 | S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 134 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT04790695 | Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab | completed | Phase 2 | 1 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT02125136 | Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer(NEOLAP) | completed | Phase 2 | 168 | AIO-Studien-gGmbHOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02259725 | Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 3 | University of Southern CaliforniaOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT01303172 | A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer | completed | Phase 2 | 110 | Immodulon Therapeutics LtdINDUSTRY | 5 | Nov 10, 2021 | clinicaltrials |
| NCT01660711 | A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | completed | Phase 2 | 22 | Endeavor HealthOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT03410914 | Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy(PATCH-DP) | completed | Phase 2 | 52 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 3, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jul 21, 2023source: clinicaltrials